

Immunosuppressive Activity of the Ethanol Extract of *Sedum sarmentosum* and Its Fractions on Specific Antibody and Cellular Responses to Ovalbumin in Mice

Feng Qin) Hong-Xiang Sun*)

) C A , Z 310029, . C
(: 86-571-869-71091; : 86-571-869-71091; - : @ . .)
) A , 225300, . C

Sedum sarmentosum ()
(A)
C , 0.25, 0.5, 1.0 , A 0.1 14. B
A (C A)-, ()-, A-
2 B , 1,
A

Introduction. *Sedum sarmentosum* BUNGE (C) -

C , 1 . 2 5 , 6 9 , 10 ,
11 , - 12 , 13 ,
12 14 17 , 16 18 ,
2 16 19 , 10 20 , 21 23 ,
5 24 25 .

S. sarmentosum

S. sarmentosum
26 .

S. sarmentosum

2700 C & B . 5 (2008)

22 23 .

2 20 . , -

C 27 30 , *S. sarmentosum*

() *S. sarmentosum*

2 5 , 2 .

in vitro in vivo.


Results and Discussion.

31 .

32 33 . A



in vitro in vivo, -7-O-β-D-

B (1),



1. Effect of EESS on Splenocyte Proliferation and . A -


B- ,




1. Effect of the EtOH extract of *A. baumannii* (A56) on mitogen-stimulated splenocyte proliferation (SI; Exper. Part). \pm s.d. (n = 4). μ g/ml

*: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$. C: A ().


2. *Effect of EESS on the OVA-Specific Serum Antibody Response in OVA-Immunized Mice.*





2. Dose-dependent inhibitory effect of the EtOH extract of *C. albicans* (C.A.) on OVA- or mitogen-stimulated splenocyte proliferation in OVA-immunized mice.

Figure 2 shows the stimulation index (SI) for Con A, LPS, and OVA in mice treated with Control, CsA (0.1 mg), EESS (0.25 mg), EESS (0.5 mg), and EESS (1.0 mg). The results show that EESS treatment significantly inhibits the stimulation index for all three mitogens, with the highest inhibition observed for OVA. Statistical significance is indicated by asterisks (*, **, ***) and letters (a, aa, aaa) above the bars.




3. Dose-dependent inhibitory effect of the EtOH extract of *C. albicans* (C.A.) on OVA-specific IgG, IgG1, and IgG2b antibodies in OVA-immunized mice.

Figure 3 shows the absorbance at 492nm for IgG, IgG1, and IgG2b in mice treated with Control, CsA (0.1 mg), EESS (0.25 mg), EESS (0.5 mg), and EESS (1.0 mg). The results show that EESS treatment significantly inhibits the absorbance for all three antibodies, with the highest inhibition observed for IgG2b. Statistical significance is indicated by asterisks (*, **, ***) and letters (a, aa, aaa) above the bars.

3. Immunosuppressive Activity of Four Fractions of EESS.

Fig. 4,


Fig. 5.



4. Effect of the EtOH extract of *Centropomus* (*C. ruber*), and its fractions on Con A- and OVA-stimulated splenocyte proliferation in OVA-immunized mice. C. L.

A: 14, 0.25, 0.5, 1.0, 7, 5, (SI; Exper. Part).
 *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$.
 B: ; A ;

Sephadex LH-20



5. Effect of the EtOH extract of *C. glabrata* (CGE), and its fractions on OVA-specific IgG, IgG1, and IgG2b antibodies in OVA-immunized mice. C. glabrata

A 14, 1, 0.25, 0.5, 1.0 7 5 A-
Part). ± . . (n = 5).
*: p < 0.05, **: p < 0.01, ***: p < 0.001;
p < 0.01, : p < 0.001; ; A ; B :

1 in vitro 39 . 1 B
 $3.44 \pm 0.05\%$. 1 B
 in vitro in vivo *S. sarmentosum*.

Conclusions.

in vitro , A- . A , B
S. sarmentosum .
 C .

Experimental Part

General. (A), 3-(4,5- -2,5- -2H-
 (), A (C A), -1640 ,
 Sigma Chemical Co. (A),
 Southern Biotech. Assoc. (B , A ,
 (C) Hangzhou Sijiqing Corp.,
 (A) Zhejiang Wanma Pharm Co. Ltd, A (C A,)
 Hangzhou Huadong Medicine Co. Ltd, Z .

Experimental Animals. () 18 22
 Zhejiang Experimental Animal Center (C . 22-2001001, , C)
 1 . 24 ± 18 , $50 \pm 10\%$, 12- /12-
 . A . C
 Institute for Experimental Animals

Plant Material. *Sedum sarmentosum* BUNGE , Z
 , C , 2004. A (. 20040612)

Laboratory of Nature Drug, C A , Z , C ,
 . Xiang-Ji Xue C , Z

Preparation and Analysis of Extract. *S. sarmentosum* 408
 (3) 70%
 2 . A (1700 \times g, 30),
 458 ca .
 157.15 (; 5.24% (w/w)).
 (A B .
 , A B , B

0.22- μ Millipore , C.
 1 B Symmetry® C18 (250 \times

4.6 . , 5 μ) / 2 35:65
 Waters 2996 PDA

Water 600E C 10 /
 A . 0.22- μ Millipore , 0.89% .

Limulus (Zhejiang A and C Biological, Z, C).
 Splenocyte Proliferation Assay. Hank' (Sigma),
 (1500 × g 48 10), ^4C (0.8% (w/v)). A
 (1640 12 mM HEPES (7.1), 0.05 mM 2-
 , 100 μ / 100 μ / 10% C). C 95%.
 (Nunc) 1×10^7 / 100 μ , C A
 (5 μ /), (10 μ /), 1640 C A
 (0.1 100.0 μ /) 200 μ (5% C₂, A 44, 50 μ
). 378
 (2 /) 4 . (1400 ×
 g, 5), 200 μ .
 (192 μ 8 μ 1 C_H) 15 ,
 A 570 630- (SI)

Administration and Immunization.

28 .
 200 μ A 1 Alum 0.2
 . A 2 . B 0.25, 0.5,
 1.0 () 0.1 0.2 . 7 A (C A,
 .
 , A-

Splenocyte Proliferation Assay.

96- (Nunc) 1×10^7 2(/ 31 - 222
 0 0 213.9()-451.9()-

Statistical Analysis.

Student's t -test, $p < 0.05$

2004 13 1360002) Zhejiang Provincial Science and Technology Council (

参考文献

1. , , Z. , *J. Tradit. Chin. Vet. Med.* **2006**, 6, 33.
2. A. , , -C. Z. , *Phytochemistry* **1998**, 49, 2607.
3. , , , *Lishizhen Med. Mater. Med. Res.* **2001**, 12, 888.
4. , , , *Lishizhen Med. Mater. Med. Res.* **2002**, 13, 714.
5. , , Z. , , , , *Chem. Pharm. Bull.* **2007**, 55, 1185.
6. , , , *Chin. J. Microbiol. Immunol.* **1982**, 1, 145.
7. , , , *Pharmacol. Clin. Chin. Mater. Med.* **1995**, 5, 30.
8. , , Z. , , , *Pharmacol. Clin. Chin. Mater. Med.* **2000**, 16, 19.
9. B.-Z. Z. , *Pharmacol. Clin. Chin. Mater. Med.* **2001**, 12, 430.
10. , , , C. , , C. , , C. , *J. Ethnopharmacol.* **2000**, 70, 177.
11. , , , B. , *J. Nutr. Sci. Vitaminol.* **2004**, 50, 100.
12. , , , B. , *Biol. Pharm. Bull.* **2004**, 27, 2035.
13. Z. , , , Z. , *Food Sci.* **2006**, 27, 89.
14. , , , A. B. , *Phytochemistry* **1996**, 41, 503.
15. A. , , *Chin. Tradit. Herb. Drugs* **1997**, 28, 517.
16. , , Z. , , *Chin. Tradit. Herb. Drugs* **2001**, 32, 305.
17. , , , , *J. Beijing Univ. Tradit. Chin. Med.* **2003**, 26, 59.
18. A. , , , -C. Z. , *J. China Pharm. Univ.* **1997**, 28, 271.
19. , C. , , , *China J. Chin. Mater. Med.* **2006**, 31, 41.
20. , , , *Phytochemistry* **1996**, 41, 1319.
21. , , , Z. , , , *Acta Pharmacol. Sin.* **1982**, 40, 273.
22. , C. , , Z. , , B. , *Bioorg. Med. Chem. Lett.* **1993**, 3, 1343.
23. , Z. , , Z. , , -C. , , B. , , *Bioorg. Med. Chem. Lett.* **2002**, 12, 3543.
24. , , Z. , , , , *Chem. Pharm. Bull.* **2007**, 55, 435.
25. , , , Z. , , , , *J. Nat. Prod.* **2007**, 90, 575.
26. , , , Z. , , , C. , , , *J. Mol. Med.* **1996**, 74, 583.
27. , , , *J. Ethnopharmacol.* **2005**, 102, 424.
28. , , , *J. Ethnopharmacol.* **2005**, 101, 31.
29. , , , *Chem. Biodivers.* **2006**, 3, 754.
30. -B. Z. , , , *Chem. Biodivers.* **2007**, 3, 967.
31. , , , *Nat. Rev. Drug Discovery* **2002**, 1, 229.
32. , C. , *Int. Immunopharmacol.* **2005**, 5, 1.
33. A. , , C. , *Drugs* **2007**, 67, 1167.
34. , C. C. , A. , C. , *Vaccine* **1997**, 15, 48.
35. , , A. C. , , A. , , *Biochem. Pharmacol.* **2004**, 68, 621.
36. , , , Z. , , *Org. Biomol. Chem.* **2006**, 4, 2483.

37. H. H. CHEN, *Adv. Exp. Med. Biol.* **1998**, 439, 175.
38. A. H. CHEN, *Microcirculation* **2000**, 7, 29.
39. H. H. CHEN, H. H. CHEN, H. H. CHEN, H. H. CHEN, H. H. CHEN, H. H. CHEN, H. H. CHEN, H. H. CHEN, H. H. CHEN, H. H. CHEN, *Chin. J. Exp. Tradit. Med. Formulae* **2006**, 12, 29.

Received November 1, 2007